Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Using a peer-reviewed methodology that provides robust, unbiased drug phase success rates and timeline metrics by treatment indication, Pharmapremia enables you to make strong, informed decisions about your drug development pipeline.
Pharmapremia gives you the ability to accurately benchmark internal and external R&D candidates’ chances of approval and potential development timelines. You can use these benchmarks to make informed decisions about drug pipeline prioritization, partnerships and acquisitions.
How it can help
Pharmapremia allows you to look at product success factors across the variables that matter to you and your business. Its robust dataset includes detailed information from the entire drug-development industry, from big pharma to private biotech, oncology to orphan diseases.
This data gives you an exclusive window into drug development pipelines and paints a fuller, clearer picture of how the industry is performing.
How it works
Effectively manage your portfolio risk by accessing comprehensive data sets including Probability of Overall Success (POS), Likelihood of Approval (LOA) and Phase and Overall Duration.
Pharmapremia covers over 8,000 programs including over 2,200 in oncology, over 1,100 in orphan diseases, and over 500 indications.
Comprehensive data sets allow you to spot and hedge against dangers
Examine components critical to clinical and regulatory success
Construct crucial points of reference to help measure your success
Our proven success rate methodology has been published in, Nature Biotechnology
Pharmapremia
10 May 2018
Drug development – it’s an area rife with risk, but with great risk often comes great rewards. An area notoriously prone to failure is oncology, and nowhere is accurate risk assessment more critical. Developing Cancer Treatments is HARD! But is everyone bad at it? is a view into this failure-prone area from Pharmapremia.
Topic Cancer
Pharmapremia
21 Jul 2017
Presented by: Robert Jeng, Senior Scientific Analyst, Will Akie, Product Manager for Pharmapremia, and Ellen Moore of Pharma Consulting.
Topic Cancer
Pharmapremia
29 Jun 2017
Drill deeper into industry-standard data using peer-reviewed methodology to gain insights you can bank on. Pharmapremia can bring confidence to the accuracy of your benchmarks.
New York, USA
Ellen specializes in
+17 year(s) experience
Support the development and validation of your strategic plans and ensure commercial decisions are based on marketplace realities. Datamonitor Healthcare offers expert coverage of key diseases, treatments, companies, drugs, market access and market trends. Our primary research with physicians, payers, and KOLs (key opinion leaders) informs our treatment standards data and patient-based forecasts.
Get a window into what the leading players across the biopharma, medtech, and diagnostics industries are thinking, as well as important insight into what your competitors are doing. Build your strategy with In Vivo.
Looking for more products Product Finder
Request a Demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
